8-K: Denali Capital Amends Merger Agreement with Semnur to Facilitate Financing

Denali Capital Acquisition Corp. has amended its merger agreement with Semnur Pharmaceuticals, Inc. to allow for the issuance of additional shares for potential private placement financing and advisor compensation, while maintaining the original exchange ratio.

Summary

• Denali Capital Acquisition Corp. (Denali) entered into Amendment No. 2 to its Merger Agreement with Semnur Pharmaceuticals, Inc. (Semnur) and Denali Merger Sub Inc. on July 22, 2025.
• The amendment modifies the definitions of the Exchange Ratio and Merger Consideration.
• This modification facilitates the issuance of additional shares of Semnur common stock prior to the closing of the Business Combination.
• The additional shares are intended for potential private placement financing or for issuance to advisors and other service providers for services rendered.
• The amendment explicitly maintains the 1.25-to-1 exchange ratio for the Business Combination.
• The Business Combination involves Merger Sub merging with Semnur, with Semnur surviving as a wholly owned subsidiary of Denali.

Sentiment

Score: 6

Explanation: The amendment is a positive procedural step that facilitates the ongoing merger and potential financing, indicating progress towards closing the Business Combination.

Positives

• The amendment facilitates potential private placement financing, which could strengthen the combined company's capital position.
• It allows for the issuance of shares to advisors and service providers, streamlining compensation for key contributors.
• The 1.25-to-1 exchange ratio remains unchanged, providing consistency for existing shareholders regarding the merger terms.

Risks

• General economic, political, and business conditions could impact the Business Combination.
• There is a risk of the parties being unable to consummate the Business Combination or an event occurring that could terminate the Merger Agreement.
• Potential legal proceedings may be instituted against the parties following the announcement of the Business Combination.
• An unsolicited offer from another party for an alternative business transaction could interfere with the Business Combination.
• The approval of Semnur's stockholders or Denali's shareholders for the transaction may not be obtained.
• Failure to realize the anticipated benefits of the Business Combination, potentially due to delays or difficulties in integrating the businesses of Semnur and Denali.
• The Business Combination could disrupt current plans and operations due to its announcement and consummation.
• The combined company's ability to grow, manage growth profitably, and retain key employees is a risk.
• The amount of redemption requests made by Denali's shareholders could impact the transaction.
• Inability to obtain or maintain the listing of the post-acquisition company's securities on Nasdaq or OTC Markets following the Business Combination.
• Costs related to the Business Combination could be higher than anticipated.

Future Outlook

The Business Combination between Semnur and Denali is expected to proceed, with the amendment facilitating potential future financing and compensation for advisors. Denali anticipates mailing a definitive proxy statement/final prospectus to shareholders for approval of the Business Combination and related matters.

Industry Context

This filing pertains to a Special Purpose Acquisition Company (SPAC) completing a de-SPAC transaction, a common mechanism for private companies to go public. The amendment addresses a procedural step to facilitate capital raising and operational aspects typical in complex merger processes.

Corporate Governance

Stakeholder Impact

• Shareholders: Will vote on the Business Combination and may experience potential dilution from additional shares issued for financing or advisor compensation, though the core exchange ratio is maintained.
• Employees: The filing mentions the risk of retaining key employees for the combined company.

Next Steps

• Denali will mail a definitive proxy statement/final prospectus and other relevant documents to its shareholders.
• An extraordinary general meeting of shareholders will be held to approve the Business Combination and related matters.
• A record date will be established for voting on the Business Combination.

Key Dates

Recommendation

This filing is a procedural update to an existing merger agreement, facilitating potential financing and advisor compensation. It does not provide new financial performance data or significant changes to the core merger terms (like the exchange ratio). As such, it's a step towards closing the previously announced Business Combination, warranting a 'hold' recommendation for investors awaiting the merger's completion and subsequent performance.

Keywords

Merger Agreement, SPAC, Denali Capital Acquisition Corp., Semnur Pharmaceuticals, Business Combination, Private Placement, Exchange Ratio, SEC Filing, 8-K, Corporate Action